FDA approves agent for RA patients who do not respond to methotrexate

November 7, 2012

FDA has approved tofacitinib (Xeljanz, Pfizer) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

Related Content:

News